172.00
前日終値:
$171.38
開ける:
$171.26
24時間の取引高:
783.24K
Relative Volume:
0.60
時価総額:
$19.20B
収益:
$9.54B
当期純損益:
$841.00M
株価収益率:
23.12
EPS:
7.44
ネットキャッシュフロー:
$1.02B
1週間 パフォーマンス:
+1.40%
1か月 パフォーマンス:
-3.64%
6か月 パフォーマンス:
+5.74%
1年 パフォーマンス:
+24.47%
Quest Diagnostics Inc Stock (DGX) Company Profile
DGX を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
DGX
Quest Diagnostics Inc
|
172.00 | 18.94B | 9.54B | 841.00M | 1.02B | 7.44 |
![]()
TMO
Thermo Fisher Scientific Inc
|
403.75 | 151.18B | 42.90B | 6.52B | 6.72B | 17.05 |
![]()
DHR
Danaher Corp
|
190.47 | 134.17B | 23.82B | 3.77B | 4.90B | 5.15 |
![]()
IDXX
Idexx Laboratories Inc
|
515.55 | 40.60B | 3.93B | 894.97M | 837.70M | 10.82 |
![]()
A
Agilent Technologies Inc
|
113.28 | 31.27B | 6.53B | 1.26B | 1.31B | 4.35 |
![]()
IQV
Iqvia Holdings Inc
|
141.02 | 23.88B | 15.50B | 1.33B | 2.16B | 7.34 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-04-02 | 開始されました | Redburn Atlantic | Buy |
2025-03-04 | ダウングレード | Citigroup | Buy → Neutral |
2025-01-06 | アップグレード | Leerink Partners | Market Perform → Outperform |
2024-12-17 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2024-12-10 | 再開されました | Jefferies | Buy |
2024-10-23 | アップグレード | Robert W. Baird | Neutral → Outperform |
2024-08-28 | 再開されました | Evercore ISI | In-line |
2024-07-10 | アップグレード | Citigroup | Neutral → Buy |
2024-02-26 | 開始されました | Leerink Partners | Market Perform |
2024-02-07 | アップグレード | Jefferies | Hold → Buy |
2024-01-03 | 開始されました | Barclays | Equal Weight |
2023-12-12 | アップグレード | BofA Securities | Neutral → Buy |
2023-06-29 | 開始されました | Piper Sandler | Neutral |
2023-05-02 | ダウングレード | BofA Securities | Buy → Neutral |
2023-04-03 | アップグレード | Citigroup | Sell → Neutral |
2023-01-23 | 開始されました | Evercore ISI | In-line |
2022-11-17 | ダウングレード | Citigroup | Neutral → Sell |
2022-08-22 | 再開されました | Morgan Stanley | Equal-Weight |
2022-04-04 | ダウングレード | Citigroup | Buy → Neutral |
2022-02-23 | ダウングレード | UBS | Buy → Neutral |
2022-02-02 | ダウングレード | Jefferies | Buy → Hold |
2022-01-28 | ダウングレード | Deutsche Bank | Buy → Hold |
2021-05-04 | アップグレード | UBS | Neutral → Buy |
2021-03-12 | ダウングレード | Robert W. Baird | Outperform → Neutral |
2020-10-21 | アップグレード | Argus | Hold → Buy |
2020-07-29 | アップグレード | KeyBanc Capital Markets | Sector Weight → Overweight |
2020-07-14 | アップグレード | BofA Securities | Neutral → Buy |
2020-06-09 | アップグレード | Wells Fargo | Underweight → Equal Weight |
2020-06-02 | アップグレード | Deutsche Bank | Hold → Buy |
2020-04-28 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2020-04-27 | アップグレード | Citigroup | Neutral → Buy |
2020-04-27 | アップグレード | Wolfe Research | Underperform → Peer Perform |
2020-03-27 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2020-01-08 | 開始されました | Wells Fargo | Underweight |
2020-01-07 | ダウングレード | Barclays | Overweight → Equal Weight |
2019-12-19 | アップグレード | BofA/Merrill | Underperform → Neutral |
2019-07-15 | ダウングレード | Goldman | Neutral → Sell |
2019-04-02 | アップグレード | Jefferies | Hold → Buy |
2019-03-18 | 再開されました | Credit Suisse | Neutral |
2019-01-31 | ダウングレード | Argus | Buy → Hold |
2019-01-17 | 開始されました | UBS | Neutral |
2019-01-03 | ダウングレード | BofA/Merrill | Neutral → Underperform |
2018-12-03 | ダウングレード | BofA/Merrill | Buy → Neutral |
2018-11-30 | ダウングレード | Goldman | Buy → Neutral |
すべてを表示
Quest Diagnostics Inc (DGX) 最新ニュース
Quest Diagnostics Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Quest Diagnostics (DGX) Participates in Upcoming Oppenheimer Meeting | DGX Stock News - GuruFocus
HOLX vs. DGX: Which Women's Health-Focused Stock Is the Better Pick? - The Globe and Mail
Is Wall Street Bullish or Bearish on Quest Diagnostics Stock? - inkl
Is Wall Street Bullish Or Bearish On Quest Diagnostics Stock? - Barchart.com
Quest Diagnostics' $4M Rest Break Settlement Gets Initial OK - Law360
Quest Diagnostics (DGX) Announces Results of 2025 Annual Meeting of Stockholders - GuruFocus
Quest Diagnostics Inc (DGX) Shares Gap Down to $171.44 on May 21 - GuruFocus
What's Driving Quest Diagnostics Stock's 25.6% Rally in a Year? - Yahoo Finance
Quest Diagnostics stock hits all-time high of $179.37 By Investing.com - Investing.com Nigeria
Director Diaz Luis was granted 1,203 shares, increasing direct ownership by 42% to 4,054 units (SEC Form 4) - Quantisnow
Quest Diagnostics to Speak at the William Blair 45th Annual Growth Stock Conference - PR Newswire
Lung Cancer Diagnostics Market Outlook: Opportunities in Early - openPR.com
Here's Why Quest Diagnostics (DGX) is a Strong Momentum Stock - Yahoo Finance
Quest Diagnostics CEO Reveals Future Growth Strategy: Key Insights Coming at William Blair Conference - Stock Titan
Here's Why Quest Diagnostics (DGX) is a Strong Value Stock - Yahoo Finance
Insider Sell: Mark Delaney Sells Shares of Quest Diagnostics Inc (DGX) - GuruFocus
Quest Diagnostics Keeps Dividend at $0.80 per Share, Payable July 21 to Shareholders as of July 7 - marketscreener.com
Quest Diagnostics (DGX) Declares Consistent Dividend - GuruFocus
Quest Diagnostics Declares Quarterly Cash Dividend - PR Newswire
Quest Diagnostics : Forbes Names Quest Diagnostics One of America's Best Large Employers - marketscreener.com
Quest Diagnostics Declares Quarterly Cash Dividend, Payable on July 21, 2025 - marketscreener.com
Is Quest Diagnostics Incorporated's (NYSE:DGX) Recent Stock Performance Influenced By Its Fundamentals In Any Way? - Yahoo
Should You Continue to Retain DGX Stock in Your Portfolio? - TradingView
Oncologists Report Seeing More Advanced Cancers and Say Current Tests Are Not Catching Cancer Recurrence Early Enough, New Quest Diagnostics Report Finds - Quantisnow
Global Immunodiagnostics Market to Cross the USD 32 Billion by 2032 | DelveInsight - GlobeNewswire Inc.
Quest Diagnostics (DGX) Sees Raised Target Price by JP Morgan | - GuruFocus
Nike To $70? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Quest Diagnostics (DGX) Receives Price Target Increase from JPMo - GuruFocus
Take the Zacks Approach to Beat the Markets: ADMA Biologics, Limbach, Quest Diagnostics in Focus - MSN
Quest Diagnostics Stock: A Leader But Waiting For Better Price (NYSE:DGX) - Seeking Alpha
Quest Settles Fired Black Phlebotomist's Retaliation Suit - Law360
Bullish on Quest Diagnosis Inc. - The Globe and Mail
This Company Extended Its Post-Earnings Rally to Record Highs - The Globe and Mail
Labcorp beats quarterly profit estimate on diagnostic test demand - Reuters
Fitch elevates Quest Diagnostics’ rating to ’BBB+’ with stable outlook By Investing.com - Investing.com Canada
Fitch elevates Quest Diagnostics’ rating to ’BBB+’ with stable outlook - Investing.com
Piper Sandler Adjusts Price Target on Quest Diagnostics to $200 From $180, Maintains Neutral Rating - marketscreener.com
Decoding Quest Diagnostics Inc (DGX): A Strategic SWOT Insight - GuruFocus
Here's How Much You Would Have Made Owning Quest Diagnostics Stock In The Last 5 Years - Benzinga
Truist Financial Keeps Their Hold Rating on Quest Diagnostics (DGX) - The Globe and Mail
These Analysts Boost Their Forecasts On Quest Diagnostics After Better-Than-Expected Q1 Earnings - Benzinga
Morgan Stanley Adjusts Quest Diagnostics Price Target to $182 From $172, Maintains Overweight Rating - marketscreener.com
Baird Adjusts Quest Diagnostics Price Target to $194 From $191, Maintains Outperform Rating - marketscreener.com
Jefferies Adjusts Quest Diagnostics Price Target to $195 From $190, Maintains Buy Rating - marketscreener.com
Quest Diagnostics (DGX) Sees Price Target Increase Following Str - GuruFocus
Mizuho Securities Adjusts Quest Diagnostics Price Target to $190 From $189 - marketscreener.com
Quest Diagnostics (DGX) Sees Price Target Increase Following Strong Q1 Results | DGX Stock News - GuruFocus
A Glimpse Into The Expert Outlook On Quest Diagnostics Through 12 Analysts - Benzinga
Quest Diagnostics Incorporated (NYSE:DGX) Q1 2025 Earnings Call Transcript - Insider Monkey
Truist Raises Price Target on Quest Diagnostics to $190 From $182, Keeps Hold Rating - marketscreener.com
Quest Diagnostics Inc (DGX) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):